Stem cells deliver new type 1 diabetes therapy
Earlier this month, San Diego-based ViaCyte announced that it was conducting human tests using an islet-cell replacement candidate product for patients with type 1 diabetes. The product, PEC-Direct, produces pancreatic progenitor cells that can replace damaged or missing pancreatic cells. …
